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Results: A total of 26 lesions were included in the analysis. 
Median follow-up was 14 months (3-41 months). Thirteen 
were metastatic lesions with histology as breast cancer, 
medulloblastoma, adenoid cystic among others. Response 
rates were: 31% complete response and partial response / 
stable at 69%. 13 benign lesions highlighting arteriovenous 
malformations, neurofibroma and melanocytoma. Response 
rates for this group: complete response in 8%, partial 
response / stable at 92%. During the follow-up time only 5 
patients had relapsed 100% to distance. Median overall 
average dose was 21 Gy (14-35 Gy), the median was three 
fractions (1-5 Fractions), median prescription isodose was 
83% (77-88%) with an average coverage of 97.27% (93.13-
100%). There were no data as myelopathy ≥ Grade II 
associated to treatment in the whole cohort, the most 
common symptom after treatment was fatigue. 
 
Conclusion: The treatment of intraspinal tumors with image-
guided robotic SBRT, has proven to be a feasible,safe and 
effective option for treatment, where treatment options are 
scarce. In our experience, the data are encouraging and 
comparable with those reported by other authors. 
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Purpose or Objective: Adult brain stem gliomas are rare 
accounting for 1-2% of adult gliomas. They are heterogeneous 
with varying clinical and radiological presentation. Prognosis 
remains poor because of limited surgical options and 
radiotherapy still remains the main treatment option. We 
report our clinical experience of treating brain stem glioma. 
 
Material and Methods: A Retrospective review was made to 
analyze the clinical presentation, diagnosis, treatment 
outcome and survival in adult brain stem glioma patients 
treated at Shaukat Khanum Memorial Cancer Hospital Lahore. 
Between July 2007 and August 2014. 
 
Results: 46 patients were identified from Hospital record 
system. Diagnosis was mostly based on radiological findings 
with MRI brain and biopsy was done only in 11 patients. 98% 
of the patients were treated with radiotherapy as a first line 
treatment on presentation and 1 patient was kept under 
close surveillance which was treated on progression. Median 
radiotherapy dose used ranged between (20-60Gy) with a 
median dose of 51Gy. Age of the patients ranged from 18 to 
72 years (median 33 years) with a Male to female ratio of 
3:1.Median follow up duration was 9 months (range 1-72). 
Radiological response was seen in 65% (13% partial & 52% 
stable) of the patients. The median overall survival (OS) for 
entire cohort was 10 months. One and two year OS rates 
were 46% and 25% respectively. Radiological Low grade 
Glioma showed a median survival of 11.5 months and was 
found to be 9.5 months for High grade Glioma. (p=0.864). 
ECOG Performance status 0,1,2 and 3 showed median survival 
of 13.6, 11.5, 6 and 3 months respectively (p=.02) 
 
Conclusion: Survival still remains dismal despite high 
radiotherapy dose. The role of cytogenetics and 
chemotherapy should be explored to improve outcome. 
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Purpose or Objective: 
Background: Brain metastases (BM) are the most common 
CNS malignancies. They represent an important cause of 
morbidity and mortality in cancer patients. In the literature, 
few studies have evaluated the efficacy of stereotactic 
reirradiation (SRT) for recurrent brain metastases as a 
salvage treatment option after a prior radiotherapy.  
Objectives: This study reports the clinical outcome and 
tolerance of repeat irradiation with CyberKnife robotic 
stereotactic delivery in patients with recurrent brain 
metastases and a history of prior cerebral radiotherapy. 
Overall survival (OS), intracranial progression-free survival 
(PFS), local control (LC) and prognostic factors associated 
with overall survival (OS) were evaluated. 
 
Material and Methods: Patients treated from April 2010 to 
January 2015 for recurrent brain metastases were 
retrospectively included. Univariate and multivariable 
analyses included age, performance status, recursive 
partitioning analysis (RPA), extratracranial disease control, 
and time from initial RT to SRT. The prior radiotherapy was 
WBRT for 27 patients (dose from 30 Gy to 45 Gy) , 
radiosurgery with Gamma knife for 8 patient (dose from 18 
Gy to 25 Gy) and hypo fractionated stereotactic radiotherapy 
in 2 patients. The tumor size ranged from 1to 4 cm (median 2 
cm).  
 
Results: In total, 37 Patients with 53 recurrent brain 
metastases and a median age of 58 years (Range 33-82 years) 
were included. The median number of metastases per patient 
was 2 (range 1-4), treated with a median dose of 21 Gy 
(range 10-36) per treatment, with a median of 3 fractions 
(range 1-9) per patient. The median follow-up was 10,1 
months (range 1-19 months). The OS rate from the SRT was 
57,2%( IC 95%: 34.6-74.6). Two (5%) of 12 deaths were from 
neurologic causes. The median PFS was 5.8 months (IC 95%: 
3.6-9.3). On multivariate analysis, controlled extracranial 
disease is correlated with better overall survival 31% (IC 95%: 
15-50; p= 0,005). Adverse radiation events developed was 
acceptable.  
 
 
